pasireotide 40 MG Injection

Known as: PASIREOTIDE 40MG/KIT SA INJ SUSP, PASIREOTIDE 40MG/KIT INJ,SUSP,SA [VA Product], pasireotide LAR 40 MG Injection 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
02420122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2018
2018
PURPOSE Medullary thyroid cancer (MTC) is a neuroendocrine tumour of the thyroid C cells. Pasireotide, a multi-receptor targeted… (More)
Is this relevant?
Review
2016
Review
2016
Pasireotide (Signifor(®)) long-acting release (LAR) is a next-generation somatostatin receptor ligand (SRL) approved for… (More)
Is this relevant?
2016
2016
BACKGROUND Acromegaly is a rare disorder characterized by the over-production of growth hormone (GH). Patients often experience a… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2016
2016
OBJECTIVE The aim of this study was to assess the efficacy (response rate centered on 80%) of a somatostatin analog with high… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2016
Review
2016
Morbidity and mortality rates in patients with active acromegaly are higher than the general population. Adequate biochemical… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2015
2015
Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2014
2014
A large, randomized, double-blind, Phase III core study demonstrated that pasireotide LAR was significantly superior to… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2014
2014
Somatostatin receptors (SSTRs) already act as important roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with… (More)
Is this relevant?
2012
2012
OBJECTIVE This study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PKs) of different doses of a long… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?